Orexo AB
STO:ORX
Orexo AB
Net Income (Common)
Orexo AB
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Orexo AB
STO:ORX
|
Net Income (Common)
-kr203m
|
CAGR 3-Years
3%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-14%
|
|
|
Calliditas Therapeutics AB
STO:CALTX
|
Net Income (Common)
-kr480.4m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-69%
|
CAGR 10-Years
N/A
|
|
|
Camurus AB
STO:CAMX
|
Net Income (Common)
kr428.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
E
|
Enzymatica AB (publ)
STO:ENZY
|
Net Income (Common)
-kr53.2m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-5%
|
|
|
S
|
Swedencare AB (publ)
STO:SECARE
|
Net Income (Common)
kr98.9m
|
CAGR 3-Years
22%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
I
|
InDex Pharmaceuticals Holding AB
STO:FLERIE
|
Net Income (Common)
-kr228m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
Orexo AB
Glance View
Orexo AB engages in the development of pharmaceuticals based on innovative drug delivery technologies. The company is headquartered in Uppsala, Uppsala and currently employs 121 full-time employees. The company went IPO on 2005-11-09. The company focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The firm has four commercialized products, several projects developed in partnership, as well as three development programs. The firm's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The firm operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
See Also
What is Orexo AB's Net Income (Common)?
Net Income (Common)
-203m
SEK
Based on the financial report for Dec 31, 2024, Orexo AB's Net Income (Common) amounts to -203m SEK.
What is Orexo AB's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-14%
Over the last year, the Net Income (Common) growth was -58%. The average annual Net Income (Common) growth rates for Orexo AB have been 3% over the past three years , and -14% over the past ten years .
You don't have any saved screeners yet